A hardy rodent with 'extraordinary' anticancer defences

April 10, 2017, Hokkaido University
The naked mole rat (Heterocephalus glaber) is the longest-living rodent (longevity, 30 years) and exhibits extraordinary resistance to cancer. Credit: Hokkaido University

Scientists are getting closer to understanding how naked mole rats, the world's longest living rodent species, avoid cancer, which could lead to safer stem cell therapies for human diseases.

Mole live up to 30 years, 10 times longer than mice, and captured colonies almost never show any type of cancer. Understanding these animals' anticancer mechanisms may help advance human treatment in the future, according to a collaborative research team from Hokkaido and Keio universities in Japan.

The team took skin tissue from adult mole rats and reprogrammed the cells into a type of stem cell called induced (iPSCs). Like , iPSCs are capable of becoming any type of tissue in the body and scientists hope human iPSCs can be used to treat diseases. Their major drawback is their tendency to form tumours when immaturely re-transplanted back into animals.

Unlike iPSCs from other animal species, tumours did not form when mole rat iPSCs were inserted into the testes of mice with extremely weak immune systems. Upon further investigation, the team found that a tumour-suppressor gene, called alternative reading frame (ARF), which is normally suppressed in mouse and human iPSCs, remained active in the mole rat iPSCs.

The team also found that ERAS, a gene that causes mouse embryonic stem cells and iPSCs to demonstrate tumour-like growth, was inactive in the mole rat iPSCs. The mice grew large tumours when the researchers disabled the ARF gene, forced the expression of the mouse ERAS gene in the rat iPSCs, and then inserted them into the mice.

These findings could help researchers figure out how human iPSCs can be used for treating patients without forming tumours. Further research into the detailed mechanisms underlying cancer resistance in the may contribute to the development of non-tumourigenic human iPSCs, enabling safer cell-based therapeutics, says Kyoko Miura of Hokkaido University.

Explore further: African subterranean animal exhibits 'extraordinary' cancer resistance

Related Stories

Induced pluripotent stem cells at risk for rejection

May 13, 2011

(PhysOrg.com) -- Biologists at UC San Diego have discovered that an important class of stem cells known as "induced pluripotent stem cells," or iPSCs, derived from an individual's own cells, could face immune rejection problems ...

New research refutes claim iPSCs are prone to immune response

January 10, 2013

(Medical Xpress)—Researchers in Japan have injected induced pluripotent stem cells (iPSCs) from mice back into genetically identical mice and report that doing so caused no immune reaction. This contradicts the results ...

Study provides hope for some human stem cell therapies

August 20, 2015

An international team of scientists headed by biologists at UC San Diego has discovered that an important class of stem cells known as human "induced pluripotent stem cells," or iPSCs, which are derived from an individual's ...

Recommended for you

Cells lacking nuclei struggle to move in 3-D environments

January 20, 2018

University of North Carolina Lineberger Comprehensive Cancer Center researchers have revealed new details of how the physical properties of the nucleus influence how cells can move around different environments - such as ...

Microbial communities demonstrate high turnover

January 19, 2018

When Mark Twain famously said "If you don't like the weather in New England, just wait a few minutes," he probably didn't anticipate MIT researchers would apply his remark to their microbial research. But a new study does ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.